RGCC International

18/12/2025

🎉 Reflecting on a remarkable 2025 at RGCC!

As 2025 draws to a close, we take a moment to reflect on a year marked by scientific progress, collaboration, and continued commitment to advancing personalized oncology.

This year, strengthened its global presence through international gatherings, scientific conferences, and collaborative research initiatives that united leading oncologists, healthcare practitioners, and researchers from around the world. We also celebrated important milestones, including the launch of the InVyomma Plus test.

As we look ahead to 2026, we remain dedicated to expanding the frontiers of precision medicine and supporting clinicians in providing truly personalized cancer care.

15/12/2025

Have you read our recently published poster, “Cell fusion model to investigate a potential origin of circulating tumor cells”?

Presented last month at the 7th Advances in Circulating Cells Meeting in Thessaloniki, Greece, the study explores the cell fusion process, the merging of the membranes of two or more cells into one hybrid cell, which is associated with cancer initiation, progression, and metastasis. It particularly focuses on the fusion of and immune cells, which can create hybrid cells with unique properties, including drug resistance, immune evasion, and cancer progression. Therefore, the project aimed to establish an in vitro cell fusion model to investigate this important biological process.

📄 Explore the study and all our published research: rgcc-international.com/published-articles/

11/12/2025

We’re proud to share that in 2025, RGCC researchers published six scientific articles, further contributing to the global understanding of personalized oncology.

Our 2025 publications include:
📄 The continual problem of crossing survival curves in clinical trial analysis and methods for effectively addressing it: A narrative review
📄 Assessment of protein expression and enumeration of circulating tumor cells in various cancer types
📄 Cell fusion model to investigate a potential origin of circulating tumor cells
📄 Enumeration and immunophenotype of circulating tumor cells in colorectal cancer patients
📄 Second-line therapy adjustment for advanced pancreatic cancer using circulating tumor cells: Preliminary results
📄 Adjusting treatment strategies using circulating tumor cells: Preliminary results on metastatic colorectal cancer

Each study reflects our ongoing commitment to advancing cancer diagnostics, refining therapeutic strategies, and improving patient outcomes.

🔗 All publications are available on our website:

Experts in developing and providing personalised cancer genetic tests for doctors and patients, RGCC is a specialist medical genetics company based in Switzerland, with laboratories worldwide.

09/12/2025

🔬 New Study Highlights Breakthrough in Ovarian

A real‑world study shows that analysis can guide personalized treatment and improve outcomes for women with advanced or recurrent ovarian cancer. 📊 Using 's test, researchers analyzed CTC counts, biomarkers, chemosensitivity, and mRNA profiling, enabling physicians to tailor therapies more precisely and extend time on treatment. 💡These findings add to growing evidence that CTC‑guided approaches are shaping the future of precision medicine — reducing toxicity, improving survival, and transforming cancer care.

➡️ Find more info and the publication here: https://bit.ly/studyOC

04/12/2025

Throwback post!

Last August, our Founder & Director, Dr. Ioannis Papasotiriou, joined Samael Tejada and Dr. Christopher Davis, MD, on the Healthy Point of View Podcast.
During the discussion, Dr. Papasotiriou shared his thoughts on the sensitivity of personalized tests and how ’s advanced cancer screening tools are transforming early detection and personalized treatment strategies.

📺 Watch the full episode: https://bit.ly/rgcc-pod

02/12/2025

Unboxing our InVyomma Plus test 👇
A simple at-home collection kit backed by powerful science.

The InVyomma Plus test focuses on profiling the gut microbiome and its association with different types of cancer. The test aids in diagnosing, confirming, or ruling out various conditions associated with .

Learn more: rgcc-international.com/tests/

27/11/2025

We’re proud to announce that RGCC presented a scientific poster at the DGHO 2025 Annual Meeting of the German, Austrian, and Swiss Societies for Hematology and Medical Oncology, held in Cologne, Germany (24–27 October 2025).

Our poster, titled “Assessment of Protein Expression and Enumeration of Circulating Tumor Cells in Various Cancer Types,” reflects RGCC’s ongoing commitment to advancing the understanding of circulating tumor cells (CTCs) and their role in cancer diagnosis, prognosis, and treatment.

With more than 6,800 participants, including physicians, scientists, and researchers, DGHO 2025 provided an exceptional opportunity for interdisciplinary collaboration and knowledge exchange, highlighting new developments in hematology and oncology.

📄 Read the full e-poster here:

Experts in developing and providing personalised cancer genetic tests for doctors and patients, RGCC is a specialist medical genetics company based in Switzerland, with laboratories worldwide.

24/11/2025

Our Oncotrace test is a powerful monitoring tool designed to assess progression. Through a simple blood draw, Oncotrace detects and analyzes circulating cells (CTCs), evaluating their presence, enumeration, and immunophenotype. This information helps determine how advanced the cancer is and the potential for metastatic spread.

By tracking CTC dynamics over time, Oncotrace enables physicians to monitor disease progression, evaluate treatment effectiveness, and make informed decisions about therapeutic strategies.

🔗 Learn more: rgcc-international.com/tests/oncotrace/

13/11/2025

As part of our ongoing commitment to corporate social responsibility, RGCC is proud to support the “Schnitte” project, run by CVJM Halle e. V., an organization dedicated to helping children living in poverty in Halle (Saale), Germany,

Through our sponsorship of the “Kinder-Hilfe-Mobil”, a newly acquired vehicle, the organization can continue to deliver essential services such as:

🚐 Regular food deliveries and meal support
🚐 Transportation to schools and kindergartens
🚐 Excursions and leisure activities for children
🚐 Collection and distribution of donated goods and food

RGCC will sponsor this project for the next five years, contributing to the continued operation and outreach of this meaningful community initiative.

Last week, we were honored to take part in the ceremonial handover in Halle (Salle), represented by our colleague Sabine Klatt.

At RGCC, we remain committed to supporting initiatives that foster care and well-being within our communities.

11/11/2025

🎥 Prof. Georgia Gioula, Professor of Medical Microbiology and Virology, explains how ’s InVyomma Plus test provides clinicians with powerful insights to guide personalized treatment plans.

InVyomma Plus integrates next-generation sequencing and advanced bioinformatics to map how microbes interact with the human body, while also measuring short-chain fatty acids in stool samples for a deeper look at bacterial balance and activity.

The result? Actionable data that helps physicians make more informed, targeted therapeutic decisions.

👉 Learn more about InVyomma Plus and RGCC’s full range of diagnostic tests: rgcc-international.com/tests/

06/11/2025

In a recent study, Statistician George Beis and our Director, Dr. Ioannis Papasotiriou, explored how different statistical tests perform when the proportional hazards (PH) assumption doesn’t hold in immuno-oncology trials.

Their findings show that while methods like weighted log-rank (GW), MK-S, and NY1/NY2 tests can better detect early or delayed treatment effects, no single test fits all scenarios. The authors recommend using a combination of robust, data-driven approaches to ensure accuracy and transparency in survival analyses.

📊 You can find all our published studies here:

Experts in developing and providing personalised cancer genetic tests for doctors and patients, RGCC is a specialist medical genetics company based in Switzerland, with laboratories worldwide.

03/11/2025

Join us this as we shine a light on men’s health. From prostate and testicular cancer to mental health, men’s wellbeing matters.

At , we’re committed to transforming cancer care through precision diagnostics with a special focus on early detection that saves lives.

Let’s continue the conversation this Movember and support research that truly changes lives. Learn more about Movember here: https://ch.movember.com/en/?home